Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   38002   clinical trials with a EudraCT protocol, of which   6235   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2017-004132-11
    Sponsor's Protocol Code Number:VX17-659-102
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2018-03-05
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2017-004132-11
    A.3Full title of the trial
    A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)
    Estudio en fase III, aleatorizado, doble ciego y controlado para evaluar la eficacia y la seguridad de la politerapia con VX-659 en pacientes con fibrosis quística, heterocigotos para la mutación F508del y una mutación de la función mínima (F/MF)
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A Study to Evaluate the Efficacy and Safety of VX-659 Drug in Combination With Other Drugs in Subjects With Cystic Fibrosis
    Un estudio para evaluar la eficacia y seguridad de VX-659 en combinación con otros fármacos en sujetos con fibrosis quística
    A.4.1Sponsor's protocol code numberVX17-659-102
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorVertex Pharmaceuticals Incorporated
    B.1.3.4CountryUnited States
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportVertex Pharmaceuticals Incorporated
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationVertex Pharmaceuticals Incorporated
    B.5.2Functional name of contact pointClinical Trials and Medical Info
    B.5.3 Address:
    B.5.3.1Street Address50 Northern Avenue
    B.5.3.2Town/ cityBoston, MA
    B.5.3.3Post code02210
    B.5.3.4CountryUnited States
    B.5.5Fax number+1510 595 8183
    B.5.6E-mailmedicalinfo@vrtx.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameVX-659/Tezacaftor/Ivacaftor
    D.3.2Product code VX-659/TEZ/IVA
    D.3.4Pharmaceutical form Film-coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNVX-659
    D.3.9.2Current sponsor codeVX-659
    D.3.9.3Other descriptive nameVX-659
    D.3.9.4EV Substance CodeSUB184589
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number120
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNTEZACAFTOR
    D.3.9.1CAS number 1152311-62-0
    D.3.9.2Current sponsor codeVX-661
    D.3.9.4EV Substance CodeSUB188271
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number50
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNIVACAFTOR
    D.3.9.1CAS number 873054-44-5
    D.3.9.2Current sponsor codeVX-770
    D.3.9.4EV Substance CodeSUB33103
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number75
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Kalydeco 150 mg film-coated tablets
    D.2.1.1.2Name of the Marketing Authorisation holderVertex Pharmaceuticals (Europe) Limited
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community Yes
    D.2.5.1Orphan drug designation numberEU/3/008/556
    D.3 Description of the IMP
    D.3.1Product nameIvacaftor
    D.3.2Product code VX-770
    D.3.4Pharmaceutical form Film-coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNIVACAFTOR
    D.3.9.1CAS number 873054-44-5
    D.3.9.2Current sponsor codeVX-770
    D.3.9.4EV Substance CodeSUB33103
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number150
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboFilm-coated tablet
    D.8.4Route of administration of the placeboOral use
    D.8 Placebo: 2
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboFilm-coated tablet
    D.8.4Route of administration of the placeboOral use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Cystic fibrosis
    Fibrosis quística
    E.1.1.1Medical condition in easily understood language
    Cystic fibrosis
    Fibrosis quística
    E.1.1.2Therapeutic area Diseases [C] - Respiratory Tract Diseases [C08]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level PT
    E.1.2Classification code 10011762
    E.1.2Term Cystic fibrosis
    E.1.2System Organ Class 10010331 - Congenital, familial and genetic disorders
    E.1.3Condition being studied is a rare disease Yes
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To evaluate the efficacy of VX-659 in triple combination (TC) with tezacaftor (TEZ) and ivacaftor (IVA) in subjects with cystic fibrosis (CF) who are heterozygous for F508del and a minimal function mutation (F/MF subjects)
    Evaluar la eficacia de VX-659 en combinación triple (CT) con tezacaftor (TEZ) e ivacaftor (IVA) en sujetos con fibrosis quística (FQ) que son heterocigotos para la mutación F508del y una mutación de función mínima (sujetos F/FM).
    E.2.2Secondary objectives of the trial
    • To evaluate the safety of VX-659 in TC with TEZ and IVA
    • To evaluate the pharmacodynamics (PD) of VX-659 in TC with TEZ and IVA
    • To evaluate the pharmacokinetics (PK) of VX-659, TEZ, and IVA when administered in TC
    • Evaluar la seguridad de VX-659 en CT con TEZ e IVA.
    • Evaluar la farmacodinámica (FD) de VX-659 en CT con TEZ e IVA.
    • Evaluar la farmacocinética (FC) de VX-659, TEZ e IVA cuando se administra en CT.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Subject (or his or her legally appointed and authorized representative) will sign and date an informed consent form (ICF), and, when appropriate, an assent form.
    2. Willing and able to comply with scheduled visits, treatment plan, study restrictions, laboratory tests, contraceptive guidelines, and other study procedures.
    3. Age 12 years or older, on the date of informed consent.
    4. Confirmed diagnosis of CF as determined by the investigator.
    5. Heterozygous for F508del and an MF mutation. If the screening CFTR genotype result is not received before randomization, a previous CFTR genotype laboratory report may be used to establish eligibility. Subjects who have been randomized and whose screening genotype does not confirm study eligibility must be discontinued from the study.
    6. Forced expiratory volume in 1 second (FEV1) value ≥40% and ≤90% of predicted mean for age, sex, and height (equations of the Global Lung Function Initiative [GLI] at the Screening Visit. Spirometry measurements must meet American Thoracic Society/European Respiratory Society criteria for acceptability and repeatability.
    7. Stable CF disease as judged by the investigator.
    8. Willing to remain on a stable CF treatment regimen through completion of study participation.
    1. El paciente (o su representante legal autorizado) firmará y fechará un formulario de consentimiento informado (FCI) y, cuando proceda, un formulario de asentimiento.
    2. El paciente debe estar dispuesto a, y ser capaz de cumplir con, las visitas programadas, el plan de tratamiento, las restricciones del estudio, los análisis clínicos, las directrices sobre anticonceptivos y otros procedimientos del estudio.
    3. Tener un mínimo de 12 años en la fecha del consentimiento informado.
    4. Contar con un diagnóstico confirmado de CF según lo determine el investigador.
    5. Ser heterozigótico para F508del y una mutación de MF (genotipos F/MF, consulte el Apéndice A para ver las mutaciones idóneas). Si el resultado del genotipo CFTR de selección no se recibe antes de la aleatorización, para establecer la idoneidad puede usarse un informe de un análisis previo del genotipo CFTR. Tienen que retirarse del estudio los pacientes a los que se haya aleatorizado y cuyo genotipo de selección no confirme la idoneidad para el estudio (Sección 9.8).
    6. Volumen expiratorio forzado (FEV1, por sus siglas en inglés) valor > 40 % y < 90 % de valor promedio previsto para su edad, género y altura (ecuaciones de la Iniciativa de función pulmonar global Global Lung Function Initiative [GLI])9 en la visita de selección. Las espirometrías deben cumplir los criterios de la American Thoracic Society/European Respiratory Society10 de idoneidad y repetibilidad.
    7. FQ estable, a criterio del investigador.
    8. El paciente debe estar dispuesto a permanecer en un régimen estable de tratamiento de FQ (según se define en la Sección 9.5) hasta la finalización de su participación en el estudio.
    E.4Principal exclusion criteria
    1. History of any illness or any clinical condition that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study drug(s) to the subject. This includes, but is not limited to, the following:
    • Clinically significant cirrhosis with or without portal hypertension
    • Solid organ or hematological transplantation.
    • Alcohol or drug abuse in the past year, including, but not limited to, cannabis, cocaine, and opiates, as deemed by the investigator.
    • Cancer, except for squamous cell skin cancer, basal cell skin cancer, and Stage 0 cervical carcinoma in situ (all 3 with no recurrence for the last 5 years)
    2. History of hemolysis.
    3. Glucose-6-phosphate dehydrogenase (G6PD) deficiency, defined as G6PD activity less than the lower limit of normal (LLN) or 70% of the mean of the LLN and the upper limit of normal (ULN), whichever is greater. A documented historical quantitative G6PD activity value measured in an established laboratory that runs the assay routinely and obtained during a prior Vertex study or as part of routine clinical care may be used to establish eligibility.
    4. Any of the following abnormal laboratory values at screening:
    • Hemoglobin <10 g/dL
    • Total bilirubin ≥2 × ULN
    • Aspartate transaminase (AST), alanine transaminase (ALT), gamma-glutamyl transferase (GGT), or alkaline phosphatase (ALP) ≥3 × ULN
    • Abnormal renal function defined as glomerular filtration rate ≤50 mL/min/1.73 m2 (calculated by the Modification of Diet in Renal Disease Study Equation) for subjects ≥18 years of age and ≤45 mL/min/1.73 m2 (calculated by the Counahan-Barratt equation) for subjects aged 12 to 17 years (inclusive)
    5. An acute upper or lower respiratory infection, PEx, or changes in therapy (including antibiotics) for sinopulmonary disease within 28 days before the first dose of study drug (Day 1).
    6. Lung infection with organisms associated with a more rapid decline in pulmonary status (including, but not limited to, Burkholderia cenocepacia, Burkholderia dolosa, and Mycobacterium abscessus). For subjects who have had a history of a positive culture, the investigator will apply the following criteria to establish whether the subject is free of infection with such organisms:
    • The subject has not had a respiratory tract culture positive for these organisms within the 12 months before the date of informed consent.
    • The subject has had at least 2 respiratory tract cultures negative for such organisms within the 12 months before the date of informed consent, with the first and last of these separated by at least 3 months, and the most recent one within the 6 months before the date of informed consent.
    7. An acute illness not related to CF (e.g., gastroenteritis) within 14 days before the first dose of study drug (Day 1).
    8. Ongoing or prior participation in a study of an investigational treatment within 28 days or 5 terminal half-lives (whichever is longer) before screening. The duration of the elapsed time may be longer if required by local regulations.
    9. Use of prohibited medications, within the specified window before the first dose of study drug (Day 1).
    10. Pregnant or nursing females. Females of childbearing potential must have a negative pregnancy test at screening (serum test) and Day 1 (urine test).
    11. The subject or a close relative of the subject is the investigator or a subinvestigator, research assistant, pharmacist, study coordinator, or other staff directly involved with the conduct of the study at that site. However, an adult (aged 18 years or older) who is a relative of a study
    staff member may be randomized in the study provided that
    • the adult lives independently of and does not reside with the study staff member, and
    • the adult participates in the study at a site other than the site at which the family member is employed.
    1. Antecedentes de cualquier enfermedad o cualquier dolencia médica que, en opinión del investigador, pudiera confundir los resultados del estudio o suponer un riesgo añadido a la administración del fármaco o fármacos al paciente. Se incluyen, entre otras:
    • Cirrosis clínicamente significativa con o sin hipertensión portal.
    • Trasplante de un órgano sólido o hematológico.
    • Alcoholismo o abuso de sustancias durante el último año, incluidas, entre otras, cannabis, cocaína y opiáceos, en opinión del investigador.
    • Cáncer, con la excepción de cáncer de piel de células escamosas, cáncer de piel de células basales y carcinoma cervical en estadio 0 localizado (en los 3 casos sin recurrencia en los últimos 5 años).
    2. Antecedentes de hemólisis.
    3. Deficiencia de la glucosa-6-fosfato deshidrogenasa (G6PD), definida como una actividad de la G6PD inferior al límite inferior de la normalidad (LIN) o 70 % de la media del LIN y el límite superior de normal (LSN), el valor que sea más alto. Para establecer la idoneidad se puede usar un valor de la actividad de la G6PD cuantitativo histórico documentado medido en un laboratorio establecido que ejecute el ensayo de manera rutinaria y obtenido durante un estudio de Vertex anterior o como parte de la atención médica de rutina.
    4. Cualquiera de las siguientes anomalías analíticas en la selección:
    • Hemoglobina < 10 g/dl
    • Bilirrubina total > 2 veces el LSN
    • Aspartato transaminasa (AST), alanina transaminasa (ALT), gamma-glutamil transferasa (GGT) o fosfatasa alcalina (ALP) > 3 x LSN
    • Función renal anormal definida como tasa de filtración glomerular < 50 ml/min/1,73 m2 (calculada según la ecuación del estudio Modificación de la alimentación en la nefropatía (Modification of Diet in Renal Disease))11, 12 en pacientes > 18 años de edad y < 45 ml/min/1,73 m (calculada según la ecuación Counahan-Barratt)13 en pacientes con edades comprendidas entre los 12 y los 17 años de edad (incluidas)
    5. Una infección aguda de las vías respiratorias altas o bajas, PEx o cambios en el tratamiento (antibióticos incluidos) para la enfermedad sinopulmorar en los 28 días anteriores a la primera dosis del fármaco del estudio (día 1).
    6. Infección pulmonar por microorganismos asociados a un deterioro más rápido del estado pulmonar (Burkholderia cenocepacia, Burkholderia dolosa y Mycobacterium abscessus, entre otros). En los pacientes con antecedentes de cultivo positivo, el investigador aplicará los criterios siguientes para establecer si tienen o no infección por esos microorganismos:
    • El paciente no ha tenido ningún resultado positivo en un cultivo del tracto respiratorio para estos microorganismos en los 12 meses anteriores a la fecha del consentimiento informado.
    • El paciente ha tenido al menos 2 resultados negativos en cultivos del tracto respiratorio para esos organismos en los 12 meses anteriores a la fecha del consentimiento informado, con una distancia entre el primero y el último de estos cultivos de al menos 3 meses y el más reciente se realizó en los últimos 6 meses antes de la fecha del consentimiento informado.
    7. Una enfermedad aguda no relacionada con la FQ (p. ej., gastroenteritis) en los 14 días anteriores a la administración de la primera dosis del fármaco del estudio (día 1).
    8. Está participando o ha participado previamente en un estudio de un tratamiento en investigación en los últimos 28 días o 5 semividas terminales (el que sea más largo) antes de la selección. La duración del tiempo transcurrido puede ser mayor si lo exige la normativa local.
    9. Uso de medicamentos prohibidos según se definen en la Tabla 9-2, en el margen de tiempo especificado antes de la primera dosis del fármaco del estudio (día 1).
    10. Mujeres embarazadas o en periodo de lactancia. Las mujeres con capacidad de procrear tienen que tener un resultado negativo en la prueba de embarazo en la selección (análisis en suero) y en el día 1 (análisis de orina).
    11. El paciente o un familiar cercano del mismo es el investigador o un investigador asociado, ayudante de la investigación, farmacéutico, coordinador del estudio u otro miembro del personal que participa directamente en la realización del estudio en ese centro. Sin embargo, se puede aleatorizar en el estudio a un adulto (de al menos 18 años de edad) que sea familiar de un miembro del personal del estudio, siempre que:
    • viva independientemente y no resida con el miembro del personal del estudio, y
    • participe en el estudio en un centro que no sea el centro en el que trabaja su familiar.
    E.5 End points
    E.5.1Primary end point(s)
    Absolute change in percent predicted forced expiratory volume in 1 second (ppFEV1) from baseline at Week 4
    Cambio absoluto en el volumen espiratorio forzado porcentual previsto en 1 segundo (VEFpp1) en la semana 4 respecto al inicio.
    E.5.1.1Timepoint(s) of evaluation of this end point
    At Week 4
    En la semana 4
    E.5.2Secondary end point(s)
    1. Absolute change in ppFEV1 from baseline through Week 24
    2. Number of pulmonary exacerbations (PEx) through Week 24
    3. Absolute change in SwCl from baseline through Week 24
    4. Absolute change in Cystic Fibrosis Questionnaire - Revised (CFQ-R) respiratory domain score from baseline through Week 24
    5. Absolute change in body mass index (BMI) from baseline at Week 24
    6. Absolute change in SwCl from baseline at Week 4
    7. Absolute change in CFQ-R respiratory domain score from baseline at Week 4
    8. Time-to-first PEx through Week 24
    9. Absolute change in BMI z-score from baseline at Week 24
    10. Absolute change in body weight from baseline at Week 24
    11. Safety and tolerability assessments based on adverse events (AEs), clinical laboratory values, ECGs, vital signs, and pulse oximetry
    12. PK parameters of VX-659, TEZ, M1-TEZ, and IVA
    1. Cambio absoluto en el valor de VEFpp1 desde el inicio hasta la semana 24.
    2. Número de reagudizaciones pulmonares (ReP) hasta la semana 24.
    3. Cambio absoluto en la concentración de cloruro en sudor (ClSu) en la semana 24 respecto al inicio.
    4. Cambio absoluto en la puntuación del dominio respiratorio del cuestionario sobre la FQ revisado (CFQ-R) desde el inicio hasta la semana 24.
    5. Cambio absoluto en el índice de masa corporal (IMC) en la semana 24 respecto al inicio.
    6. Cambio absoluto en la concentración de ClSu en la semana 4 respecto al inicio.
    7. Cambio absoluto en la puntuación del dominio respiratorio del CFQ-R en la semana 4 respecto al inicio.
    8. Período hasta primera ReP hasta la semana 24.
    9. Cambio absoluto en la puntuación z del IMC en la semana 24 respecto al inicio.
    10. Cambio absoluto en el peso corporal en la semana 24 respecto al inicio.
    11. Evaluaciones de seguridad y tolerabilidad basadas en los acontecimientos adversos (AA), valores de los análisis clínicos, ECG, constantes vitales y pulsioximetría.
    12. Parámetros FC de VX-659, TEZ, M1-TEZ e IVA.
    E.5.2.1Timepoint(s) of evaluation of this end point
    1. Through Week 24
    2. Through Week 24
    3. Through Week 24
    4. Through Week 24
    5. At Week 24
    6. At Week 4
    7. At Week 4
    8. Through Week 24
    9. At Week 24
    10. At Week 24
    11. Day 1, 15, Weeks 4,8, 12, 16, 24, ETT Visit, Safety Follow up Visit
    12. Day 1, Weeks 4, 8, 12, 16, ETT Visit
    1. Hasta la semana 24
    2. Hasta la semana 24
    3. Hasta la semana 24
    4. Hasta la semana 24
    5. En la semana 24
    6. En la semana 24
    7. En la semana 24
    8. Hasta la semana 24
    9. En la semana 24
    10. En la semana 24
    11. Día 1, 15, semanas 4,8, 12, 16, 24, visita ETT, visita de seguridad de seguimiento
    12. Día 1, semanas 4, 8, 12, 16, visita ETT
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned8
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA36
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Australia
    Canada
    Denmark
    Germany
    Ireland
    Israel
    Norway
    Poland
    Spain
    Switzerland
    United Kingdom
    United States
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    The end of study is defined as the last scheduled visit or, for subjects who have been lost to follow-up, the last contact, whichever occurs later, for the latest completing subject in the study.
    El final del estudio se define como la última visita programada o, para los sujetos que se perdieron durante el seguimiento, el último contacto, lo que ocurra más tarde, para el último sujeto completo del estudio.
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years0
    E.8.9.1In the Member State concerned months8
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years0
    E.8.9.2In all countries concerned by the trial months8
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 Yes
    F.1.1Number of subjects for this age range: 120
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) Yes
    F.1.1.6.1Number of subjects for this age range: 120
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 240
    F.1.3Elderly (>=65 years) No
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state32
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 145
    F.4.2.2In the whole clinical trial 360
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Vertex Pharmaceuticals Incorporated, the sponsor of the study, may offer subjects the opportunity to enrol in an extension study if they have completed all study visits through Week 4 and are eligible. Vertex will inform subjects of this possibility in the informed consent form.
    Vertex Pharmaceuticals Incorporated, el promotor del estudio, puede ofrecer a los sujetos la oportunidad de inscribirse en un estudio de extensión si han completado todas las visitas de estudio hasta la semana 4 y son elegibles. Vertex informará a los sujetos de esta posibilidad en el formulario de consentimiento informado.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2018-05-18
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2018-05-04
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2019-02-05
    As of 1.2.2020, the UK is no longer an EU Member State. However, EU law still applies to the UK during the transition period
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2020 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice
    EMA HMA